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The aim of supportive autografting is to reduce the side effects from stem cell transplantation and avoid
procedure-related health disadvantages for patients at the lowest possible cost and resource expendi-
ture. Economic evaluation of health care is becoming increasingly important. We report clinical and
laboratory data collected from 397 consecutive adult patients (173 non-Hodgkin lymphoma, 30 Hodgkin
lymphoma, 160 multiple myeloma, 7 autoimmune diseases, and 28 acute leukemia) who underwent their
ﬁrst autologous peripheral blood stem cell transplantation (PBSCT). We considered primary endpoints
evaluating health economic efﬁcacy (eg, antibiotic administration, transfusion of blood components, and
time in hospital), secondary endpoints evaluating toxicity (in accordance with Common Toxicity Criteria),
and tertiary endpoints evaluating safety (ie, the risk of regimen-related death or disease progression
within the ﬁrst year after PBSCT). A time-dependent grading of efﬁcacy is proposed with day 21 for
multiple myeloma and day 25 for the other disease categories (depending on the length of the condi-
tioning regimen) as the acceptable maximum time in hospital, which together with antibiotics, anti-
fungal, or transfusion therapy delineates four groups: favorable (7 days on antibiotics and no
transfusions; 21 [25] days in hospital), intermediate (from 7 to 10 days on antibiotics and <3 trans-
fusions, 21 to 25 days in hospital or 7 days on antibiotics and no transfusions; from 21 to 30 days [25
to 34] in hospital), unfavorable (>7 days on antibiotics, >3 but <6 transfusions; >30/34 days in hospital
after transplantation), and very unfavorable (>10 days on antibiotics, >6 transfusions; >30 to 34 days in
hospital). The multivariate analysis showed that (1) PBSC harvests of 4  106/kg CD34 þ cells in 1
apheresis procedure were associated with a favorable outcome in all patient categories except acute
myelogenous leukemia and acute lymphoblastic leukemia (P ¼ .001), (2) 5  106/kg CD34 þ cells
infused predicted better transplantation outcome in all patient categories (P < .0001) except acute
myelogenous leukemia and acute lymphoblastic leukemia, (3) 1 or 2 aphereses (P ¼ .001) predicted good
outcome, (4) toxicity increased with higher graft volume reinfused (>500 mL) (P ¼ .002), and (5) patients
with a central venous catheter during both collection and infusion of PBSC had a more favorable outcome
post-PBSCT than peripheral access (P ¼ .007). The type of mobilization regimen did not affect theedgments on page 1675.
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Proposed Graded Clinical Endpoint
Objective E
Primary: health economic
efﬁcacy (to study the
efﬁcacy of stem cell
graft reinfusion)
D
d
Secondary: toxicity (to
evaluate toxicity after
stem cell graft
reinfusion)
D
O
f
Tertiary: safety and
disease progression
(to evaluate safety
after stem cell
graft reinfusion)
D
ANC indicates absolute neutrophiloutcome of auto-PBSCT. The present study identiﬁed predictive variables, which may be useful in future
individual pretransplantation probability evaluations with the goal to improve supportive care.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION a heterogeneous group of patients in a prospective registra-
Enumeration of CD34þ cells was shown to be useful in
the procedure of stem cell mobilization and harvest from
blood for transplantation, and it seems to be informative for
the prediction of fast or delayed 3-lineage engraftment and
blood cell recovery after high-dose therapy [1e8]. In 1998
the European Joint Accreditation Committee of the Interna-
tional Society of Hematotherapy and Graft Engineering/
European Group for Blood and Marrow Transplantation
(EBMT) prepared a regulatory document on the standards for
blood and marrow progenitor cell collection, processing, and
transplantation [9]. The major objectives were to promote
quality of medical and laboratory practice in hematopoietic
progenitor cell transplantation [9]. These standards extend
and detail pre-existing international activity to ensure that
appropriate standards of work and product quality are
established and maintained [3,4,6,9].
The aim of supportive autografting is to reduce the side
effects from high-dose therapy and avoid procedure-related
health disadvantages for patients at the lowest possible cost
and resource expenditure. Economic evaluation of health care
is becoming increasingly important. Clinical endpoints for
such evaluations have been proposed [1,2] in which the ﬁrst
objectivewas to analyze efﬁcacy, which in the context of post-
transplantation supportive care may be deﬁned by, for
example, days on antibiotics and transfusions of blood prod-
ucts; the second objective was to analyze toxicity deﬁned by
time to blood cell recovery; and the third objective was to
analyze safety as deﬁned by risk of early relapse or death.
Based on such retrospective analyses, we estimated prog-
nostic models regarding the short-term graded endpoints ins in Quality Assessment Based on a 4-Stage Gra
ndpoint
ays on antibiotics, transfusion of blood compon
ays in hospital after transplantation
ays to ANC >.5  106/L and platelets > 20  10
ther organ toxicity if appropriate, as deﬁned by
or mucositis, dermatitis, and enteritis
eath or disease recurrence
count; WHO, World Health Organization.tion and validation study [1,2,10e13].
In this study, we report data collected prospectively from
397 consecutive patients who underwent their ﬁrst autolo-
gous peripheral blood stem cell transplantation (PBSCT) based
on a myeloablative conditioning regimen. We considered
primary endpoints evaluating efﬁcacy (ie, health economic
issues, including antibiotic administration, transfusion of
blood components, and time in hospital), secondary
endpoints evaluating toxicity (in accordance with Common
Toxicity Criteria [14]), and tertiary endpoints evaluating safety
(ie, the risk of regimen-related death or disease progression
within the ﬁrst 12 months after PBSCT) [15].METHODS
Objectives and Endpoints
Based on the proposal from the EBMT subcommittee on quality
assessment of autologous stem cell graft, pretransplantation variables were
analyzed for inﬂuence on aggregated clinical endpoints chosen as indicators
for the outcome of post-transplantation supportive care, toxicity, and safety
as deﬁned in Table 1. The ﬁrst objective was to analyze cost/expenditure of
supportive care by an aggregate endpoint termed efﬁcacy, deﬁned by days
on antibiotics and use of transfusions of blood products. The second
objective was to analyze the reduction of marrow toxicity from high-dose
therapy by an endpoint termed toxicity deﬁned by the time to blood cell
recovery. The third objective was to describe patient outcome by an
endpoint termed safety deﬁned by early death or disease recurrence within
12 months. The endpoints were binary graded as favorable or unfavorable,
as deﬁned in Table 1. The selection of 21 and 25 days as the optimal
hospitalization time was due to the length of the conditioning regimen
(1 day for multiple myeloma [MM] receiving high-dose melphalan and
6 days for Hodgkin lymphoma [HL] and non-Hodgkin lymphoma [NHL]
receiving the BEAM regimen).ding Classiﬁcation to Evaluate the Health Economic Efﬁcacy
Grading
ents, Favorable: 7 days on antibiotics and no transfusions; 21
days in hospital for MM and 25 for other disease categories
(NHL, HL, AML, acute lymphoblastic leukemia, autoimmune
disease)
Intermediate: from 7 to 10 days on antibiotics and <3
transfusions; 21 days in hospital (<25 for other disease
categories),7 days on antibiotics and no transfusions; 21<
<30 days in hospital
Unfavorable: >7 days on antibiotics, >3 but <6 transfusions;
>30 days in hospital in MM and >34 for other disease
categories
Very unfavorable: >10 days on antibiotics, >6 transfusions;
>30 days in hospital in MM and >34 in other disease
categories
6/L
WHO
Favorable: ANC and platelet recovery before 14 days and no
major organ toxicity
Unfavorable: ANC and platelet recovery after 14 days and/or
organ toxicity
A toxicity novel classiﬁcation proposed by combining grade,
type, and number of adverse events:
Low: grade 0-1 and n <2 events
Intermediate: grade 1 and n >2 events
High: grade 1 and n >2 or grade 2 and n <2 events
Very high: grade 2 or 3 and n >2 events or grade 4 or 5
Favorable: Alive and without disease progression after 12
months
Unfavorable: Death or disease progression before 12 months
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Included in the study were 397 consecutive patients (study code Q01).
This was an EBMT observational study released at the end of 2004
(December 2004), and patient accrual ended in December 2011. The
following European teams provided case report forms to the secretary of the
study: Hematology Section, St. Anna Hospital, Italy (CIC 330); Section of
Hematology, Ospedale Ferrarotto BMT Unit, Italy (CIC 792); UmeåUniversity
Hospital, Sweden (CIC 731); Hematology Service, Medical Academy of
Gdansk (CIC 799) Poland; Hematology Section, Hospital of Cremona, Italy
(CIC 226); Spain Hospital de Navarra (CIC 577); Section of Hematology,
University of Warsaw (CIC 800), Poland; Hospital Virgen de la Arrixaca (CIC
323), Spain; and University Hospital, Lublin (CIC 695), Poland.
Median patient age was 51 years (range, 21 to 70). One hundred and
seventy three patients had NHL, 30 patients had HL,160 patients hadMM,10
patients had autoimmune diseases (8 with systemic sclerosis and 2 with
multiple sclerosis), 24 patients had acute myelogenous leukemia (AML), and
4 patients had acute lymphoblastic leukemia. Performance status, evaluated
by the Eastern Cooperative Oncology Group (ECOG) system, was assigned as
follows: 222 patients were assigned to ECOG 0, 101 patients ECOG 1, and 74
patients ECOG 2.
Patients were treated with different chemotherapy regimens, according
to local policy. A single line of chemotherapy was administered in 58% of the
cases before themobilization regimen; 42% of patients receivedmore than 1
line of chemotherapy (range, 2 to 4). At the time of mobilization, disease
status was as follows: among NHL patients, 97.2% were in complete remis-
sion and 2.8% in partial remission. Among MM patients, 64% had achieved
a very good partial remission and 30% of patients a partial remission;
a complete remission was achieved in the remaining MM cases (6%).
Complete remission before the stem cell mobilization procedure was also
reached in patients with AML, acute lymphoblastic leukemia, and other
diseases, according to EBMT criteria. Only 3% of patients received radio-
therapy before mobilization.
Patients enrolled in this study were treated as follows. The 273 NHL
patients (18 low-grade, 155 high-grade patients) were treated with 1 or 2
lines of chemotherapy. Most patients were treated with R-CHOP (110
patients), MACOP-B (26 patients), or CEOP (24 patients). The 29 patients
treated with 2 lines of chemotherapy received R-DHAP or R-ESHAP. Ten
patients affected by indolent NHL received treatment with a ﬂudarabine-
based regimens, whereas 16 received R-CHOP or R-CVP. The 30 HL
patients were treated with ABVD chemotherapy regimen in 24 cases and
BEACOPP in the remaining ones. Among these patients, 9 were treated with
1 line of chemotherapy, and 23 patients were treated with 2 or more lines
with a range of cycles between 3 and 8. For MM, 160 patients with newly
diagnosed myelomawere included in the study. Fifty-ﬁve were treated with
VAD regimen (range, 4 to 6 cycles); 42 were treated with thalidomide plus
dexametasone and 3 with thalidomide, melphalan, and steroids (MPT, 6 to
14 cycles), whereas the 50 remaining patients were treated with bortezomib
plus dexamethasone.
Patients with acute leukemia were treated with standard chemotherapy
regimens (ICE, DCE, or similar protocols), and complete remission was
assessed using standard criteria. Patients with autoimmune diseases were
treated according to ASTIS and ASTIMS trials.
Stem Cell Harvest
Cells were harvested when the leukocyte count in PB was at least>1000
cells/mL and the CD34þ cell count was >15/mL. The mean number of
apheresis procedures was 2.43 (.16; 95% conﬁdence interval, 0 to 6), and
9.94 liters of blood (.30; 95% conﬁdence interval, .02 to 13.8 liters) were
meanly processed in the single procedure.
Mobilization and Conditioning Regimen
A total of 183 patients received high-dose cyclophosphamide (4 g/m2)
and 31 low-dose cyclophosphamide (<4 g/m2). AmongpatientswithNHL, 46
received DHAP/ESHAP regimens; 26 received etoposide in combinationwith
daunorubicin or methotrexate or carboplatin as a mobilization regimen;
cytarabine (ARA-C) in combinationwithmethotrexate or cyclophosphamide
was administered in 25 patients; 18 patients received ifosfamide in combi-
nation with gemcitabine or vincristine or etoposide or ARA-C; and 43
patients received CHOP/CEOP mobilization regimens. Finally, 78 patients
received only granulocyte colony-stimulating factor for PBSC mobilization.
The granulocyte colony-stimulating factors used alone or in combina-
tion with chemotherapy were as follows: lenograstim in 153 cases (1 to 2
vials per day), ﬁlgrastim in 226 patients (5 to 10 mg/kg/day); pegﬁlgrastim in
18 patients (13 patients at the dose of 6 mg and 5 patients at 12 mg), and
plerixafor in 15 cases. Plerixafor was used in poor mobilizer patients who
failed a previous attempt of mobilization [16e20].
The conditioning regimens adopted in this study for auto-SCT were
as follows: BEAM (carmustine, etoposide, cytarabine, and melphalan)regimen for 152 patients affected by NHL; mitoxantrone 60 mg/m2, plus
melphalan 180 mg/m2 for 13 patients with NHL; thiotepa-CY, Bu-Cy, or
Bu-Mel for AML patients; and other regimens for other patient categories.
In MM patients 148 received melphalan 200 mg/m2, 6 patients received
melphalan 100 mg/m2, and 6 patients received a combination of
melphalan and mitoxantrone. All patients received a myeloablative
conditioning regimen. In 90% of the cases, granulocyte colony-stimulating
factor administration started 1 to 5 days after auto-SCT and continued until
the absolute neutrophil count was greater than 1000/mL for 3 consecutive
days.
Venous Access
A central venous catheter was introduced in 317 patients before auto-
SCT, whereas 80 had no central venous catheter, and transplantation was
performed using a peripheral venous access.
Data Collection (MED C Form)
Data were collected through a speciﬁc MED C form composed of seven
forms: (1) registration form (patient characteristics), (2) mobilization phase
(type and dosage of cytokine used and of chemotherapy regimen), (3) graft
evaluation form (type of apheresis machine; apheresis program; volume of
blood processed; duration [hours þ minutes]; venous access; volume
collected and information on the leukocyte, hemoglobin, and platelet count;
complications during the collection procedure; total CD34 number; type of
CD34 analysis [single or dual platform analysis]; cryopreservation procedure
[automated freezing, freezing medium, storage conditions]; reinfusion; and
graft manipulation), (4) adverse events form, (5) hospitalization form, (6)
supportive care form (use of antibiotics, dosage, and duration), and (7)
serious adverse events form, in which we listed a great number of infor-
mation relevant to the study [21,22]. Data from the MED C form were
combined with data reported in MEDA and, when available, with the MED B
form (see: http://www.ebmt.org/).
A time-dependent grading of efﬁcacy was proposed with day 21 in MM
and 25 days for other disease categories as the acceptable maximum time in
hospital, which together with antibiotics, antifungal, or transfusion therapy
delineates 4 groups: an acceptable outcome for patients discharged before
day 22 with no therapy, and an unacceptable outcome for patients who stay
in hospital >21 days on continuous therapy [15]. A 4-stage grading classi-
ﬁcation is shown in Table 1 [1,15].
Toxicity was evaluated in accordance with Common Toxicity
Criteria, as deﬁned by the World Health Organization or derived
references (ECOG, cancer research cooperative group, etc.) for mucositis,
dermatitis, and enteritis as well as grading of hematological toxicity
after stem cell infusion [14]. Concerning toxicity, the proposed grading
system is time-independent, with outcome assessed according to the
World Health Organization recommendation for grading of organ
toxicity as acceptable if toxicity is grades 0 to 2 and unacceptable if
grades 3 to 4. By tradition, the hematological toxicity has to be time-
dependent, and an evaluation has been proposed (Table 1).
Finally, evaluation of “safety” by mortality and disease recurrence
indicates an acceptable outcome if patients are alive with no disease
recurrence up to day 100 and unacceptable if the high-dose therapy is fol-
lowed by death or relapse before 1 year after PBSCT. Mortality and disease
recurrence was also evaluated 1 year after autologous bone marrow trans-
plantation. By combining efﬁcacy, toxicity, and safety parameters, a novel
classiﬁcation is proposed as shown in Table 1.
Statistical Analysis
The following variables were analyzed as potential factors inﬂuencing
post-transplantation outcome: age, pathology, bone marrow involvement at
the time of mobilization, prior chemotherapy and radiation therapy, and
type of mobilization regimen. The potential effect of the various factors on
the response variables (ie, CD34þ cell counts measured under the different
settings) were preliminarily assessed using Spearman’s rank correlation
coefﬁcients, and the differences between cohorts were evaluated both by
the nonparametric Kruskall-Wallis analysis of variance or by the Mann-
Whitney 2-sample test and, for Gaussian variables, by parametric analysis
of variance followed by LSD post-hoc comparisons.
Multivariate regression analysis was applied to determine in a stepwise
fashion the relative rank of independently signiﬁcant pretransplantation
and transplantation-related variables. The prognostic variables were used to
estimate probability for the outcome (acceptable or unacceptable),
depending on the level of CD34 numbers in the harvested graft. The
following prognostic models were considered in the analysis: sex, age,
disease, mobilization method, type of growth factor used, graft volume,
number of apheresis procedures performed, conditioning regimen, post-
transplantation growth factor administration, and number of reinfused
CD34þ cells. The univariate and multivariate statistical analyses were
Table 2
Mobilized Blood Stem Cells, Collection, and Auto-PBSCT
Characteristic Median (Range or %)
CD34þ peak (day after the start of granulocyte colony-stimulating factor with/without chemotherapy) 12 (5-21)
White blood cell count in concomitance with CD34þ peak (day after the start of granulocyte colony-stimulating factor
with/without chemotherapy)
3.1 (2-56)
Number of apheresis performed 2.2 (1-4)
Volume of apheresis processed 12,370 mL (7000-15,900)
Number of collected CD34þ cells  106/kg 8.1 (.6-23)
Number of collected CD34þ cells  106/kg per single apheresis 1.3 (.5-14)
Number of patients collecting >2  106/CD34þ cells 277/397 (69%)
Number of patients harvesting a total number of CD34  106/kg/LP >1.5 but 2 CD34þ  106/kg/LP 66 (16%)
Number of patients harvesting a total number of CD34þ  106/kg/LP >1 but 1.5 CD34þ  106/kg/LP 30 (8%)
Patients harvesting a total number of CD34þ  106/kg/LP >.5 but 1 CD34þ  106/kg/LP 24 (6%)
Volume infused of PBSC preparation at the time of transplantation, mL 373 (125-1020)
Absolute number of infused CD34þ cells (106/kg) 3.9 (1.01-12.5)
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PRIMARY ENDPOINT: HEALTH ECONOMIC EFFICACY
Figure 1. Distribution of patients in the various categories according to the
clinical endpoint related to the health economic efﬁcacy. Assessment of this
endpoint is based on the evaluation of the following parameters: antibiotic
administration, transfusion of blood components, and hospitalization time.
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groups formed by NHL, MM, and AML patients [15].
RESULTS
Circulating Blood Stem Cells, Collection, and Auto-PBSCT
The main clinical and laboratory data are given in Table 2.
Data are expressed as a median and range. Sixty-nine percent
ofpatients reachedagood level ofprogenitorcell content in the
apheresis product (3.9CD34þ106/kg/leukapheresis; range, 2
to 16.7); in particular, 136 patients harvested a total amount of
CD34  106/kg/LP, >2 and 5 CD34þ  106/kg/LP and 122
patients harvested a total amount of CD34þ  106/kg/LP <5.
Of note, < 1% (.6% of the cases) of stem cell harvests were
manipulated before transplantation. Most of them per-
formed CD34þ cell selections (CliniMacs, Miltenyi Biotec,
Cologne, Germany), and in 4 patients a purging procedure
was performed using maphosphamide.
After PBSCT, engraftment of neutrophil granulocytes
occurred at a median day 12 (range, 9 to 25), whereas
platelets engrafted at day 15 (range, 10 to 27). Patients who
received manipulated grafts showed a delayed engraftment
for both granulocytes and platelets (days 17 and 23, respec-
tively). However, this patient subgroup comprised a very
small number of patients and therefore did not affect the
statistical signiﬁcance of our data analysis.
Supportive Care
The efﬁcacy of autografting was evaluated considering the
following supportive care parameters: number of days with
fever on antibiotics, number of transfusions, and hospitali-
zation time. In 26.9% of patients examined, prophylactic
antibiotics were administered, and in 61.5% of patients anti-
biotic therapeutic administration was used for a mean
number of 16 days. The median number of days for the
therapeutic use of antimicrobial agents was 11.3.
The use of prophylactic antibiotics was found to be
associated with a signiﬁcantly lower incidence (P < .01) of
infectious disorders and, in general, with a more favorable
outcome post-PBSCT. In 4 cases, a bacterial contamination of
the apheresis product was observed; these patients were
treated with a targeted use of antibacterial therapy.
As for most parameters analyzed, transfusion of red
blood cells and platelets was 1.8 (range, 0 to 18) and 2.9
(range, 0 to 14), respectively. The median time of hospital-
ization was 26 days (range, 14 to 65). Finally, efﬁcacy results,
evaluated with our 4-stage grading classiﬁcation (Table 1),
were as follows: 16% of patients were included in stage 1
(favorable), 46% of patients were included in stage 2(intermediate), 34% of patients were included in stage 3
(unfavorable), and 4% were included in stage 4 (very unfa-
vorable) (Figure 1).
The secondary endpoint of the study was to evaluate
toxicity. Results from our novel classiﬁcation (Table 1),
described in Methods, showed that 35.7% of patients expe-
rienced a low toxicity, 23.8% of patients an intermediate
toxicity, 14.1% of patients a high toxicity, and 25.5% of
patients a very high toxicity (Figure 2).
We considered the grade and the type of the adverse
event, and the combination of the 2 parameters give rise to
the following classiﬁcation: low, toxicity grades 0 to 1
(31.2%); intermediate, toxicity grade 2 (40.9%), high, toxicity
(22.2%); and very high (5.5%).
The tertiary endpoint of the study was to evaluate the
safety after stem cell graft infusion considering regimen-
related death or disease recurrence. Concerning severe
adverse events, we found in 1.5% of patients a death event, in
1.8% of patients a severe adverse event occurred, in 2.19% of
patients a new and follow-up event occurred, and 4.7% of
patients (7 of 319) required rehospitalization. Disease relapse
occurred in .9% of patients at day 100 and in 6.8% within
1 year after auto-PBSCT in the NHL/HL patient group. The
frequency of disease relapse 1 year after auto-PBSCT was 25%
in MM and 42% in acute leukemia patients. At 12 months
after PBSCT, the death rate was 3.4%.
Figure 2. Distribution of patients in the various categories according to the
clinical endpoint related to toxicity. Assessment of this endpoint was done in
accordance with Common Toxicity Criteria. The proposed grading system is
time-independent with outcome assessed according to the World Health
Organization recommendation for grading of organ toxicity as acceptable if
toxicity is grade 0-2 and unacceptable if grade 3-4. By tradition, hematological
toxicity has to be time-dependent and an evaluation has been proposed,
according to four grades: (1) low: grade 0-1 and n <2 events; (2) intermediate:
grade 1 and n >2 events; (3) high: grade 1 and n >2 or grade 2 and n < 2
events; (4) very high: grade 2 or 3 and n >2 events or grade 4 or 5.
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In the statistical analysis, the ﬁrst point of the study,
efﬁcacy, was regarded as “quality.” In univariate analysis,
“quality” seems to be affected by venous access; in fact,
patients with a central venous catheter were associated with
a signiﬁcantly better outcome after PBSCT than patients with
peripheral venous access (P ¼ .007). Furthermore, “quality”
decreases with CD34þ volume reinfused >500 mL
(P ¼ .0001). Finally, adverse events higher than grade 3 were
found to be a statistically signiﬁcant unfavorable factor
(P ¼ .0001).
Concerning toxicity, the number of apheresis procedures
was found to be statistically signiﬁcant, as 1 or 2 apheresis
procedures was associated with less toxicity (P ¼ .001).
Toxicity increased with CD34þ cell volume reinfused
>500 mL. Finally, patients classiﬁed as poor in relation to
toxicity showed poor outcome post-PBSCT (P ¼ .0001),
according to our grading system.
In multivariate analysis, toxicity had a negative effect on
transplantation outcome because patients who experienced
higher toxicity had a poor quality transplantation (P¼ .0001).
Finally, a higher CD34þ cell volume reinfused (>500mL)was
found to increase toxicity with a statistically signiﬁcant P
value (P ¼ .002).
Concerning PBSC collection, a smaller number of apher-
esis procedures (1 or 2) was found to be statistically signiﬁ-
cant to predict good outcome compared with a larger
number of apheresis procedures (3 to 6; P ¼ .001). The
number of CD34 cells collected in each apheresis was found
to be a favorable factor, since the number of CD34þ cells
collected >4  106/kg in 1 apheresis predicted good
outcome, except for AL patients. Finally, a number of CD34þ
cells infused> 5106/kg was found to be a further favorable
factor for stem cell engraftment. No correlation among the
type of mobilization regimen, type of conditioning regimen,
type of growth factor used for the mobilization regimen, and
outcome of autologous transplantation was documented in
this study. As far as the degree of toxicity and the assessment
of the overall quality of transplantation is concerned, a center
effect was clearly documented (P < .01).DISCUSSION
Supportive reinfusion of progenitor cells after SCT ulti-
mately aims to re-establish hematopoiesis after an initial
recovery of end-stage blood circulating cells to a level
necessary for reducing the risk of side effects, such as
infections, bleeding, or anemia [10e13]. It is known that
a graft content of more than 5 million CD34þ cells/kg body
weight is safe, resulting in fast recovery of absolute
neutrophil count and platelets before days 14 and 21,
respectively, in a major fraction of patients and, most
important, only has a minor risk for engraftment failures
[10,23e33]. The aim of supportive autografting is to reduce
the side effects from high-dose therapy and to avoid
procedure-related health disadvantages for patients at the
lowest possible cost and resource expenditure. Economic
evaluation of health care is becoming increasingly impor-
tant. Clinical endpoints for such evaluations have been
proposed [1,2]. The ﬁrst objective of this proposal was to
analyze efﬁcacy, which in the context of post-
transplantation supportive care may be deﬁned by, for
example, days on antibiotics and transfusions of blood
products. The second objective was to analyze toxicity
deﬁned by time to blood cell recovery. The third objective
was to analyze safety as deﬁned by risk of early relapse or
death. Based on such retrospective analyses, we estimated
prognostic models regarding the short-term graded
endpoints in a heterogeneous group of patients in
a prospective registration and validation study.
In our study, multivariate analysis showed that either the
number of CD34 þ cells collected and reinfused >4  106
cells/kg in 1 day or the number of CD34þ cells collected and
reinfused >5  106 cells/kg is associated with more rapid
engraftment and better transplantation outcome, except for
acute leukemias patients [26e28]. The number of patients
with autoimmune diseasewas low, so the prognostic value of
CD34þ cells in this disease category still remains uncertain.
Moreover, it is obvious from such data that we will never
obtain an exact number of CD34þ cells delineating an
“insufﬁcient” or “safe” graft. We have to reconsider these
terms and change exact numbers into probabilities of
obtaining clinical efﬁcacy, avoiding toxicity, and retaining
safety, with evaluation by proper endpoints [1,2,15,34,35].
In the last decade, hundreds of reports have based their
conclusions about quality assessment on surrogate markers,
and, as suggested, it seems to be time for a move toward
evaluation based on clinically relevant factors. Such data,
although published from single centers, are not available
from multicenter trials and have to be generated in
a prospective manner. It is worth mentioning that the
introduction of PBSCT has not changed the risk of docu-
mented infections compared with the use of conventional
bone marrow grafts, although a faster neutrophil recovery is
substantially documented.
Health, economic, and life-quality considerations need to
be included in assessment of supportive hematopoietic cell
therapy. Of less importance may be the side effects (eg,
hematological toxicity) as deﬁned by time to lineage
recovery or engraftment. This protocol has proposed
a change by assessing the probabilities of obtaining primary,
secondary, or tertiary endpoints, therefore providing
evidence that engraftment and hematopoietic recovery are
not the only clinical endpoints in autografting. Such an
assessment may allow us to handle each patient individually
in daily practice by predicting not only the efﬁcacy, but also
the risk of side effects as well as safety.
F. Lanza et al. / Biol Blood Marrow Transplant 19 (2013) 1670e1676 1675To this aim, in this study we ﬁrst evaluated the efﬁcacy of
autografting by analyzing clinical endpoints beyond the
CD34þ cell number, such as supportive care, time in hospital,
and so on, and proposing a time-dependent grading of efﬁ-
cacy, as previously reported. Our results of 397 patients who
underwent an auto-SCT emphasized that only a lower
number of patients were graded as good for efﬁcacy.
In our analysis, we observed several factors affecting
toxicity in PBSCT. We did not focus just on the number of
CD34þ cells reinfused but considered the volume of CD34þ
cells reinfused. We observed that toxicity increased with
higher volume of CD34 þ cells reinfused (>500 mL). Few
studies investigated the occurrence and severity of adverse
events after auto-SCT [21,23e30], and most of them focused
on the dimethyl sulfoxide activity affecting toxicity or on the
amount of leukocyte in the apheresis product. None,
however, analyzed the CD34þ cell volume reinfused as we
did. Another important factor to predict good outcome in this
prospective study was the low number (1 or 2) of apheresis
procedures compared with a higher number of apheresis
procedures. This parameter is not often considered because
CD34þ cells collected and reinfused are preferred. In our
study, it seemed to be important to predict low toxicity and
a better transplantation outcome.
Moreover, we considered as a secondary endpoint of the
study hematological and extra-hematological toxicity with
a time-independent grading system. As previously reported,
we observed that patients with poor-grade toxicity had
a worst transplantation outcome [1,2].
Today, hematological toxicity is considered one of themore
important secondary endpoints for graft evaluation, which in
practice focuses on the primary impact of health economic
endpoints. A proposed analytic strategy of such pre-
transplantation variables deﬁnes clinically relevant primary
and secondary endpoints as, for example, supportive trans-
fusions or antibiotic administration and toxicity, respectively.
Introduction of such endpoints that are binary graded as
acceptable or unacceptable post-transplantation outcomes
may allow us to estimate prognostic models and illustrate
individual quality assessment basedonprobability evaluation.
Taken together, these data conﬁrm that further variables
other than the CD34þ cell number play a role in trans-
plantation outcome. These ﬁndings underscore the need for
a more extensive quality assessment of autologous PBSCT,
taking into account that transplantation outcome is inﬂu-
enced not only by graft content, but also by other important
parameters such as time in hospital, supportive care,
assessed in terms of blood transfusion and antibiotic therapy,
and grade of toxicity, and the occurrence of relapse or death
after transplantation.
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